SPRO - Spero Therapeutics to Present at Upcoming November Investor Conferences | Benzinga
CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer, will be available for one-on-one meetings at the Truist Securities BioPharma Symposium, to be held at the Lotte New York Palace in New York, NY, on November 8-9, 2023 and will present and be available for one-on-one meetings at the 6th Annual Evercore ISI HealthCONx Conference to be held at the Kimpton EPIC Miami Hotel in Miami, FL, on November 28-30, 2023. Details are as follows:
Truist Securities BioPharma Symposium
Investor One-on-One Meetings: Wednesday, November 8, 2023, from 8AM-5PM ET
6th Annual Evercore ISI HealthCONx Conference
Analyst Fireside Chat: Tuesday, November 28, 2023, from 7:55AM-8:15AM ET
Webcast Link: https://wsw.com/webcast/evercore39/spro/2409596
The webcast for the Evercore ISI event may also be accessed through Spero Therapeutics' website (www.sperotherapeutics.com) on the "Events and Presentations" page under the "Connect" tab. Replays will be available on the website following the conclusion of each event.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.
- Spero Therapeutics is developing SPR720 as a novel ...